Botox. It's more than just a wrinkle buster.
The blockbuster product is at the center of Valeant Pharmaceuticals' hostile play for Allergan, valued at $45 billion to $50 billion. Irvine, Calif.-based Allergan projects sales of Botox will rise to as much as $2.28 billion this year.
A little known fact: More than half of that revenue comes from therapeutic uses of Botox, rather than from cosmetic ones.